Volume : 12, Issue : 06, June – 2025

Title:

GLYCEMIC CONTROL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES: A SYSTEMATIC REVIEW

Authors :

Sager Alanazi, Fatimah alkamis, Hawraa Radhi alsuroj , Kawthar Hussain Alsaleh, Amnah Ibraheem Alhamar, Zainab Ali Alhabeeb, Marwah Hussain Alkhamis

Abstract :

Type 2 diabetes mellitus (T2DM) is a prevalent chronic metabolic disorder associated with significant morbidity and mortality, primarily due to cardiovascular complications. Glycemic control has long been considered central to diabetes management, yet the optimal level of control to reduce cardiovascular risk remains debated. This systematic review examines the relationship between glycemic control and cardiovascular outcomes in patients with T2DM. A comprehensive search of PubMed, Scopus, Embase, and the Cochrane Library was conducted for studies published between January 2000 and April 2025. Thirty-four relevant studies, including randomized controlled trials (RCTs), cohort studies, and meta-analyses, were analyzed. The findings indicate that while tight glycemic control significantly reduces microvascular complications, its impact on macrovascular outcomes such as myocardial infarction and stroke is less clear, with some studies reporting benefits and others indicating potential risks. The review emphasizes individualized glycemic targets, especially considering patient age, comorbidities, and hypoglycemia risk.

Cite This Article:

Please cite this article in press Fatimah Alkhamis et al., Glycemic Control And Cardiovascular Outcomes In Patients with type 2 Diabetes: A Systematic Review., Indo Am. J. P. Sci, 2025; 12(07).

Number of Downloads : 10

References:

1. American Diabetes Association. Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S1-S187.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998;352(9131):837-853.
3. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572.
4. ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
5. Gerstein HC, et al. The impact of intensive glucose control on cardiovascular outcomes: meta-analysis. Lancet Diabetes Endocrinol. 2015;3(6):431–440.
6. Patel A, et al. ADVANCE Collaborative Group. N Engl J Med. 2008;358(24):2560–2572.
7. Ray KK, et al. Effect of intensive glucose control on macrovascular outcomes. Lancet. 2009;373(9677):1765–1772.
8. Holman RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
9. Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
10. Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
11. Wiviott SD, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347–357.